Generated by AI
REGENXBIO Inc. is a clinical-stage biotechnology company focused on gene therapy. REGENXBIO Inc. develops and commercializes recombinant adeno-associated virus (AAV)–based treatments designed to deliver functional genes to cells and address genetic defects. Its current work centers on therapeutic programs in retinal, metabolic, and neurodegenerative diseases, supported by its proprietary NAV Technology Platform. The company also licenses its AAV gene-delivery technology to other biotechnology partners, combining internal drug development with platform licensing. REGENXBIO Inc. plays a specialized role in the biotechnology market by advancing gene therapy candidates and enabling broader use of AAV-based delivery systems across the life sciences industry.
Website9804 Medical Center Drive
Rockville, MD, 20850
United States
The latest articles about RGNX.
Regenxbio Inc (RGNX) eyes pivotal sura-vec data this quarter and a Q1 2027 BLA filing for RGX-202, backed by $251 million in cash and runway into late 2027.
Summary of Nov 11's posts. Generated by AI.
Summary of Jun 22's posts. Generated by AI.
Summary of Aug 24's posts. Generated by AI.
Summary of Aug 24's posts. Generated by AI.
Investors talking about RGNX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.